Covid-19
Conditions
Interventions
Experimental group:Paxlovid
control group:No
Sponsors
Renji Hospital, Shanghai Jiaotong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Test group: (1) Age: 18-75 years old; (2) Gender is not restricted; (3) Meet the diagnostic criteria of the Diagnosis and Treatment Program for Novel Coronavirus Pneumonia (Trial Ninth Edition); (4) Willing to use Paxlovid; (5) Patients with viral nucleic acid CT value > 35 if taking Paxlovid for less than 5 days; 2. Control group: (1) Age: 18-75 years old; (2) Gender is not restricted; (3) Meet the diagnostic criteria of the Diagnosis and Treatment Program for Novel Coronavirus Pneumonia (Trial Ninth Edition); (4) Unwilling to use Paxlovid; (5) Age, sex, body mass index, underlying disease and medication history were strictly matched with each subgroup of the clinical classification in the test group.
Exclusion criteria
Exclusion criteria: 1. Patients with advanced malignant tumor; 2. Kidney disease or severe renal insufficiency (renal function EGFR < 30ml/min/1.73m2); 3. Severe liver dysfunction (ALT/AST is more than 2.5 times the normal upper limit); 4. Other metabolic diseases other than diabetes, such as thyroid and adrenal diseases; 5. Rheumatoid immune diseases, etc. 6. Contraindications to the use of Nimatvir Tablets/Ritonavir Tablets; 7. Other circumstances that the researcher thinks are not suitable for study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fasting blood glucose;2 hours postprandial blood sugar;Glycated hemoglobin;Blood fat; | — |
Secondary
| Measure | Time frame |
|---|---|
| Covid-19 CT value; | — |
Countries
China
Contacts
Public ContactJing Ma
Renji Hospital, Shanghai Jiaotong University School of Medicine
Outcome results
None listed